Copy Paste Quotes

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older

US health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.

Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.

Continue reading...

Jun 18, 2026 US healthcare Vaccines and immunisation Flu

Need the full article?

Use the dedicated news page for the summary, then jump straight to the original source when you want the complete story.